BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis

Cheng Zhang, MD, Dan Shi, MD, Ping Yang, MD

Abstract

Background: To analyze whether BNP could be a potential biomarker for cardiac damage of breast cancer after radiotherapy.

Methods: PubMed, Web of Science, ProQuest and Medline were searched using the key words “breast cancer” (“breast tumor”, “breast neoplasm”, or “breast carcinoma”), “brain natriuretic peptide” (or BNP) and “radiotherapy” (or “radiation therapy”). Four articles were selected and analyzed using the STATA 12.0 software package. The standard mean difference (SMD) and its standard error for BNP were calculated to assess the relationship between BNP and radiotherapy for breast cancer patients.

Results: In total, 172 patients with breast cancer were identified. The pooled SMD was -0.233 (95% CI -1.113, -0.057). The pooled estimated SMD for all studies showed obvious significant difference (z=3.99, P=.000). There was no publication bias.

Conclusions: This meta-analysis suggested that BNP could be a biomarker of cardiac damage at high heart absorbed doses according to radiotherapy, especially for left breast cancer patients.

Abbreviations: 95% CI = 95% confidence intervals, BNP = brain natriuretic peptide, ESMO = European Society for Medical Oncology, IMRT = intensity modulated radiation therapy, LV = left ventricle, LVEF = left ventricular ejection fraction, MI = myocardial infarction, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, SMD = standard mean difference, TnI = troponin.

Keywords: BNP, breast cancer, radiotherapy

1. Introductions

Breast cancer is the most common cancer and the leading cause of cancer death among women worldwide. Chemotherapy and radiotherapy play crucial role in local control and metastasis of breast cancer. However, it has been reported that cardiovascular mortality are observed in breast cancer patients especially for left breast cancer after chemotherapy and/or radiotherapy. Cardiac biomarkers such as brain natriuretic peptide (BNP) and troponin (TnI) may be used to monitor cardiotoxicity and assess early signs of cardiovascular dysfunction. Plasma levels of TnI have been used as a prognostic marker of cardiac disease for high dose chemotherapy, especially for anthracyclines. However, 2 trials found that in left breast cancer patients, left ventricular ejection fraction (LVEF) did not significantly change after radiotherapy, and was not correlated with TnI levels. Hence, TnI is not considered for biomarker to cardiac damage of breast cancer patients. So, what about BNP? Could it be suitable? There had been already some articles about BNP as biomarker for heart damage in breast cancer patients. We conducted this meta-analysis to evaluate its potential role for biomarker, especially the patients who received radiotherapy and chemotherapy.

2. Methods

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An ethical approval was not necessary.

2.1. Search strategy

We identified studies in PubMed, Web of Science, ProQuest and Medline on combinations of the following keywords “breast cancer” (“breast tumor”, “breast neoplasm”, or “breast carcinoma”), “brain natriuretic peptide” (or BNP) and “radiotherapy” (or “radiation therapy”). The most recent article was updated on 2016. We also manually searched the references of related articles in this analysis.

2.2. Inclusion/exclusion criteria

Studies were considered eligible if they met the following inclusion criteria: The studies involved patients with left breast
cancer, without metastasis and recurrence. The patients underwent radical/conserving surgery followed by radiotherapy and/or chemotherapy. The articles were written as full papers in English.

Studies were excluded for the following reasons: The publications were review articles, letters, case reports, expert opinions, or meeting records. Non-human research was performed. Patients had recurrent or metastatic disease. Patients were with right breast cancer or cardiac dysfunction. The publications were not written in English.

2.3. Data extraction

To avoid the repeated inclusion of the same data, the largest study with the longest follow-up time was included if there were several published studies involving the same patients at the same research center. We included one study if different patients were included in 2 studies at the same research center. Similarly, when there were multiple sets of data in one study, such as subsets of patients with different stage disease, we listed all data in separate sets. For data extraction, eligible articles were reviewed independently by 2 investigators. Discrepancies were resolved by discussion between the reviewers prior to data extraction. In cases of different opinions, a third reviewer was consulted to reach consensus.

Means and standard deviations analyses from publications were included in our analysis. Mean and standard deviation were calculated by median, maximum, and minimum.[11]

Additional data were carefully extracted from all the eligible publications using a standardized data collection form, including first author, publication year, tumor stage, chemotherapy regimen, surgery type and other important clinical characteristics.

2.4. Statistical methods

We calculated the available statistics with SMD with 95% confidence intervals (95% CI) calculated by either random-effects model or fixed-effects model to evaluate the correlation and Z test was utilized to evaluate the effect size[12] according to means and standard deviations from every studies.

Forest plots were used to estimate BNP changes after radiotherapy and/or chemotherapy for left breast cancer patients. Heterogeneity was defined as \( P \leq .10 \) or \( I^2 > 40\% \). When homogeneity was present \( (P > .10, I^2 \leq 40\%) \),[13] a fixed effect model was used for secondary analysis. Publication bias is a major concern for all meta-analyses. Funnel plots were generated to assess potential publication bias, and \( P > .05 \) indicated no potential publication bias.[14] All statistical analyses were conducted using the STATA 12.0 software package.

3. Results

3.1. Characteristics of identified studies

According to our previously defined criteria, the initial electronic online search of PubMed databases, Web of Science, ProQest, and Medline retrieved 393,618 papers. After the selection according to the inclusive criteria, 4 eligible studies were finally included (Fig. 1).

There were totally 172 patients with breast cancer from the 4 included manuscripts. In Meinardi 2001, patients received radiotherapy after chemotherapy including left and/or right modified radical mastectomy or breast-conserving treatment. In D’Errico 2012, patients with left breast conserving surgery with radiotherapy after chemotherapy were compared with no radiotherapy. In D’Errico 2015, patients with left breast conserving surgery or modified radical hysterectomy were concerned. The BNP data was collected according to different time after radiotherapy. In Palumbo 2016, patients with left breast conserving surgery were selected and BNP were evaluated according to different time after radiotherapy. According to radiotherapy, only 3-dimensional conformal technology in Palumbo 2016 was applied, other articles were not available (Table 1).

3.2. BNP changes after radiotherapy/chemotherapy for breast cancer patients

SMD were available in 4 studies for a total of 172 patients. The pooled SMD was \(-0.233 \) (95% CI \(-1.113, -0.057\)). The heterogeneity among studies was not high \( (I^2 = 27.9\%, P = .164) \). The pooled estimated SMD for all studies showed obvious significant difference \((z = 3.99, P = .000)\) (Fig. 2).

---

Figure 1. Flow chart of study identification.
3.3. Publication bias analysis

Funnel plots were generated to assess the publication bias of the studies. These plots showed obvious symmetry and no publication bias (Fig. 3).

4. Discussions

BNP is an endogenous peptide produced initially by ventricular cardiomyocytes as a 134-aa pre-pro-peptide. Its levels were 20.3 (9.9–36.5) pg/ml and 21.1 (9.8–37.7) g/ml in patients without any...
left ventricular (LV) dysfunction and 61.5 (50–68.4) pg/ml in patients with LV dysfunction.\cite{39} BNP was secreted as a consequence of left ventricle impairment, and was elevated in heart failure and in acute coronary syndrome which includes acute myocardial infarction (MI) and unstable angina.\cite{36–39} BNP as a widely accepted marker of cardiac failure has widely used in clinical usage,\cite{36–39} especially in the diagnosis of heart failure.\cite{38,39} Cardiac dysfunction is one of complications which could affect patients survival quality, even modern radiotherapy improvements are applied.\cite{28} Biomarker for early diagnosis is emphasized to recognize the potential risk of cardiomyopathy, especially in left breast cancer patients.

According to this meta-analysis, breast cancer patients are involved, especially their treatments including surgery, chemotherapy, and radiotherapy. These treatments could induce the changes of BNP, which could be biomarker for breast cancer patients about cardiac failure. In this meta-analysis, most patients received conserving surgery for left breast according to these manuscripts. According to the results, the pooled SMD was $-0.233$ (95% CI $-1.113$, $-0.057$). The pooled estimated SMD showed obvious significant difference ($z=3.99$, $P=0.000$). These results showed that after radiotherapy, plasma levels of BNP was obvious increased especially in left breast cancer patients with significant difference. According to D’Errico 2015\cite{31} and Palumbo 2016,\cite{17,18} BNP levels were elevated after radiotherapy in 1 to 12 months and 37 to 120 months, respectively. These results reminded us that after radiotherapy, BNP variation arose earlier after treatment, and kept increasing in a very long time. However, the patients whose BNP elevated, could not be absolutely diagnosed as cardiac dysfunction. There is still no enough evidence to monitor the threshold of BNP by separating high risk potential patients. BNP could remind clinical recognition for further examinations and attentions. Hence, BNP could be a marker in follow-up for breast cancer after radiotherapy, as its stable and reliable characteristics. According to patients whose BNP elevated, more attention should be paid in case of cardiac dysfunction.

Radiotherapy plays a crucial role in early stage breast cancer after hysterectomy or conserving surgery with satisfying local control. Nevertheless, numerous epidemiological studies have shown that radiotherapy could increase cardiovascular mortality many years after treatment.\cite{21,22} The risk of cardiac mortality was 44% higher in left breast cancer patients than in those with right-sided in 6 to 24 months after radiotherapy.\cite{24–27} The early effects pericardial effusion, myocarditis and left ventricular dysfunction were induced after radiotherapy,\cite{28,29} is associated with the heart absorbed dose.\cite{29} Significant correlations between BNP and some dosimetric parameters of heart were found in those patients whose BNP values were above the threshold, and increasing correlation between BNP and hot spots of dose was showed.\cite{16} Higher values of D50% (Gy) seem to be related to BNP increase, even if it is not statistically significant. D50% (Gy) was the main parameter linked in a statistically significant. In addition, BNP values above the pathological cut-off threshold was correlated with high doses of radiation in small volumes (hot spots of dose), such as BNP and V5Gy%, D15 cm\(^3\) (Gy)/Dmean (Gy), D15 cm\(^3\) (Gy)/D50% (Gy) for the heart and V2Gy%, D1 cm\(^3\) (Gy)/Dmean (Gy), D 0.5 cm\(^3\) (Gy)/D50% (Gy) for the ventricle.\cite{3} Because 15 cm\(^3\) resulted in approximately 3% of mean heart volume, D15 cm\(^3\) (Gy) indicates a dose near the maximum dose.\cite{30} When the ratios D15 cm\(^3\) (Gy)/Dmean(Gy) and D15 cm\(^3\) (Gy)/D50% (Gy) increased, BNP elevation indicated high dose radiation for heart. However, the methods for radiotherapy about 4 manuscripts were not available except Palumbo \cite{17} by 3-dimensional conformal radiotherapy using 2 tangential fields. Hence, intensity modulated radiation therapy (IMRT), proton beam irradiation, prone positioning and breath hold are recommended to reduce heart absorbed dose.\cite{31,32} In addition, partial breast irradiation as an alternative to whole irradiation after breast conserving surgery in selected patients,\cite{33} may reduce dose to the heart in those with left breast cancer.\cite{34} And their effects on BNP need further exploring. There is some relationship between BNP and radiation dose, which could induce heart injury. Hence, in order to control cardiac dysfunction, heart dose reduction is available, and BNP as a biomarker could monitor the effects of radiation on heart because of reflecting cardiomyocytes damage induced by radiation. Finally, the response ability of cardiomyocytes to radiation could be noticed and the possibility of heart failure could be foreseen according to the breast cancer patients.

European Society for Medical Oncology (ESMO) suggests measuring BNP to evaluate cardiotoxicity during and after radiotherapy for breast cancer patients.\cite{35} BNP measurement should be performed in patients with risk factors for cardiac damage, in those who receive high doses to the heart despite modern technology.\cite{36–39} According to follow up of breast cancer patients, BNP is a potential biomarker to heart damage, and is recommended to detect gradually for a long time.

5. Conclusions

Long-term monitoring and follow-up of BNP to screen patients with cardiac insufficiency could be practical. During or after radiotherapy, myocardial fibers were damaged, which indirectly reflected the sensitivity of cardiomyocytes to radiation. Consequently, BNP could be a biomarker of cardiac damage at high heart absorbed doses according to radiotherapy, especially for left breast cancer patients.

Author contributions

Data curation: Dan Shi.
Formal analysis: Cheng Zhang, Dan Shi.
Investigation: Dan Shi.
Methodology: Cheng Zhang, Dan Shi.
Writing – original draft: Cheng Zhang, Dan Shi.
Writing – review & editing: Cheng Zhang, Dan Shi, Ping Yang.

References

[1] Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–54.
[2] Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003;49:248–52.
[3] D’Errico MP, Petruzelli MF, Giancolo EA, et al. Kinetics of B-type natriuretic peptide plasma levels in patients with left-sided breast cancer treated with radiation therapy: Results after one-year follow-up. Int J Radiat Biol 2015;91:804–9.
[4] Skyytta T, Tuohinen S, Boman E, et al. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol 2015;10:141.
[5] Fagugli RM, Palumbo B, Ricciardi D, et al. Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract 2003;95:60–66.
[6] Palumbo B, Seppe D, Lap tutelli G, et al. Usefulness of brain natriuretic peptide levels to discriminate patients with stable angina pectoris without and with electrocardiographic myocardial ischemia and patients with healed myocardial infarction. Am J Cardiol 2004;94:780–3.
[7] Lap tutelli G, Marcheschi S, Seppe D, et al. Natriuretic peptides levels are related to HDL-cholesterol with no influence on endothelium dependent vasodilatation. VASA Zeitschrift für Gefäßkrankheiten 2006;35:215–20.
[8] Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148–59.
[9] Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–327.
[10] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2012;10:364–7.
[11] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
[12] Chen H, Manning AK, Dupuis J. A method of moments estimator for dose chemotherapy. Clin Chem 2003;49:248–52.
[13] Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a random effect multivariate meta-analysis. Biometrics 2012;68:1278–84.
[14] Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a random effect multivariate meta-analysis. Biometrics 2012;68:1278–84.
[15] Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective study of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001;19:2746–53.
[16] D’Errico MP, Grimaldi I, Petruzelli MF, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys 2012;82:239–246.
[17] Palumbo I, Palumbo B, Fravolini ML, et al. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: a prospective study. Breast 2016;25:45–50.
[18] Geland JC, Goode K. Natriuretic peptides for heart failure. Fashionable? Useful? Necessary? Eur J Heart Fail 2004;6:253–5.
[19] McDonagh TA, Holmer S, Raymond I, et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004;6:269–73.
[20] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98.
[21] Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995;333:1444–55.
[22] Early Breast Cancer Trialists’ Collaborative Group. Favorable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355:1757–70.
[23] Senkus-Konek E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev 2007;33:578–93.
[24] Sarah C, Darby PM, Carolyn W, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 2003;6:537–65.
[25] Taylor CW, McGale P, Darby SC. Cardiac risks of breast-cancer radiotherapy: a contemporary view. Clin Oncol 2006;18:236–46.
[26] Roychoudhuri R, Robinson D, Putcha V, et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer 2007;7:9.
[27] Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005;63:214–23.
[28] Gagliardi G, Comonte LS, MosseBenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S77–85.
[29] Sardaro A, Petruzelli MF, D’Errico MP, et al. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol 2012;103:133–42.
[30] Measurements ICoRUs. Prescribing, recording, and reporting photon beam therapy. ICRU Rep 2010;83.
[31] Shah C, Badiyan S, Berry S, et al. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiat Oncol 2014;11:29–16.
[32] Mast ME, Vredevedel EJ, Credcoe HM, et al. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. Breast Cancer Res Treat 2014;148:33–9.
[33] Aristei C, Palumbo I, Capezzali G, et al. Outcome of a phase II prospective study on partial breast irradiation with interstitial multihole high-dose-rate brachytherapy. Radiother Oncol 2013;108:236–41.
[34] Lottmers S, Krepnner S, Lotter M, et al. Radiation exposure of the heart, lung and skin by radiation therapy for breast cancer: a dosimetric comparison between partial breast irradiation using multicatheter brachytherapy and whole breast teletherapy. Radiother Oncol 2011;100:189–94.
[35] Curtigiano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii155–166.
[36] Matzinger O, Heimsoth I, Poortmans P, et al. Toxicity at three years with conventional conformal radiotherapy for early breast cancer: the EORTC trial 22922/10925. Acta Oncol 2010;49:24–34.
[37] Thorsen LB, Thomsen MS, Overgaard M, et al. Quality assurance of RT-associated cardiac perfusion defects. Acta Oncol 2014;53:1027–34.
[38] Thorsen LB, Thomsen MS, Berg M, et al. Danish Breast Cancer Cooperative Group Radiotherapy c. CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefits versus potentially harmful effects. Acta Oncol 2014;53:1027–34.
[39] Whelan TJ, Olivotto IA, Levine MN. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 2015;373:1878–9. 

Zhang et al. Medicine (2019) 98:29. www.md-journal.com